Who are MCV-AC Vaccine Group's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Prevnar 20, PedvaxHIB®, Meningococcal Polysaccharide Diphtheria Toxoid Conjugate, Hib conjugate vaccine, Menjugate®, 4CMenb.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mcv-ac-vaccine-group.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

MCV-AC Vaccine Group — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MCV-AC Vaccine Group (MCV-AC Vaccine Group) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Conjugate vaccine. Area: Immunology / Infectious Disease.

phase 3 Conjugate vaccine Neisseria meningitidis serogroups A and C polysaccharide capsules Immunology / Infectious Disease Biologic Live · refreshed every 30 min

Target snapshot

MCV-AC Vaccine Group (MCV-AC Vaccine Group) — Beijing Minhai Biotechnology Co., Ltd. MCV-AC is a meningococcal conjugate vaccine that stimulates immune responses against multiple serogroups of Neisseria meningitidis to prevent meningococcal disease.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
MCV-AC Vaccine Group TARGET	MCV-AC Vaccine Group	Beijing Minhai Biotechnology Co., Ltd	phase 3	Conjugate vaccine	Neisseria meningitidis serogroups A and C polysaccharide capsules
Prevnar 20	pneumococcal 20-valent conjugate vaccine (PCV20)	Pfizer Inc.	marketed	Pneumococcal conjugate vaccine	Streptococcus pneumoniae capsular polysaccharides (20 serotypes)	2021-06-08
PedvaxHIB®	PedvaxHIB®	GlaxoSmithKline	marketed	Conjugate vaccine	Haemophilus influenzae type b polyribosylribitol phosphate (PRP) capsular polysaccharide
Meningococcal Polysaccharide Diphtheria Toxoid Conjugate	Meningococcal Polysaccharide Diphtheria Toxoid Conjugate	Sanofi Pasteur, a Sanofi Company	marketed	Conjugate vaccine	Neisseria meningitidis polysaccharide capsule
Hib conjugate vaccine	Hib conjugate vaccine	Public Health England	marketed	Conjugate vaccine	Haemophilus influenzae type b polysaccharide capsule
Menjugate®	Menjugate®	GlaxoSmithKline	marketed	Meningococcal conjugate vaccine	Meningococcal serogroup C polysaccharide capsule
4CMenb	4CMenb	CHU de Quebec-Universite Laval	marketed	Conjugate vaccine	Neisseria meningitidis serogroup B polysaccharide capsule

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2033-06-01 — Prevnar 20 · US 8,895,024 · Composition of matter · US
2035-06-01 — Prevnar 20 · US 10,279,033 · Method of use · US

Sponsor landscape (Conjugate vaccine class)

GlaxoSmithKline · 26 drugs in this class
Sanofi Pasteur, a Sanofi Company · 6 drugs in this class
CanSino Biologics Inc. · 3 drugs in this class
MCM Vaccines B.V. · 3 drugs in this class
Beijing Minhai Biotechnology Co., Ltd · 3 drugs in this class
Wyeth is now a wholly owned subsidiary of Pfizer · 2 drugs in this class
PT Bio Farma · 2 drugs in this class
LG Life Sciences · 2 drugs in this class
Walvax Biotechnology Co., Ltd. · 2 drugs in this class
Heinrich-Heine University, Duesseldorf · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). MCV-AC Vaccine Group — Competitive Intelligence Brief. https://druglandscape.com/ci/mcv-ac-vaccine-group. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab